18F-Flutemetamol and Plaque Vulnerability

Phase 2

• Conditions: Atherosclerosis
• Interventions: Drug: 18F-Flutemetamol PET/MRI

• Registration Number: NCT03291093
• Lead Sponsor: Maastricht University Medical Center

Brief Summary

Rationale: Amyloid beta (Ab) is mainly known for its role in Alzheimer's disease (AD) pathology. However, Ab seems not only to be involved in AD pathology, but also in atherosclerosis, which might explain the remarkable similarities in risk factors between these two pathologies. In vitro studies suggest that a major part of this association is based on the ability of amyloid to lead to macrophage activation and thus inflammation. These data lead to the hypothesis that Ab is associated with plaque vulnerability.

18F-Flutemetamol is a PET tracer with high affinity for Ab. This has been extensively studied in AD patients.

Objective: To validate 18F-Flutemetamol PET in the evaluation of plaque vulnerability.

Study design: A cross-sectional validation study. Study population: 25 adults, who have recently (\<14days) experienced a transient ischemic attack (TIA) or stroke with a carotid artery plaque of ≥30% and without evidence of another etiology than carotid atherosclerosis (i.e. cardiac or small vessel).

Of these 25 patients, 10 patients will be included who have been scheduled for carotid endarterectomy (CEA). The other 15 will be selected of patients who are not scheduled to undergo CEA.

Intervention: All patients will undergo a PET/MRI scan with 18F-Flutemetamol, either before the scheduled CEA or within the first 30 days following the cerebrovascular event. Imaging will include the carotid and coronary arteries as well as the brain.

Main study parameters/endpoints: Tracer uptake in the carotid artery will be correlated to vulnerable plaque characteristics as assessed by MRI. In the 10 CEA patients, tracer uptake and MR imaging of different plaque characteristics will be validated with plaque histology of the surgically removed specimen.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is no additional benefit for study subjects. Study subjects will receive the same treatment as non-participating patients. Patients will be screened for in- and exclusion criteria to minimize risks.

For optimal MR imaging patients will be injected with a Gadolinium based contrast agent, which is a common procedure and associated with very low risk of complications. The PET tracer 18F-flutemetamol has been studied extensively and is currently used in patients with AD. Adverse events were not frequent and mainly mild. The radioactivity dose will be around 6.8 mSv.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-09-19
• Study First Submitted QC: 2017-09-19
• Study First Posted: 2017-09-25
• Study Start: 2018-02-01
• Status Verified: 2019-01
• Last Update Submitted: 2019-07-10
• Last Update Posted: 2019-07-11
• Primary Completion: 2019-12-31
• Study Completion: 2019-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

• All patients:

  • Severe cognitive impairment, neurological deficit or comorbidity causing the study to be too high a burden for the patient or disrupting patient's co- operation with scan procedures

  • Evident other causality for stroke (cardiac embolus, small vessel disease or thrombogenic diathesis)

  • Pregnant women and nursing mothers

  • Contra-indications for MRI (49):

    • Ferromagnetic implants, such as pacemakers and other electronic implants
    • Ferromagnetic (intracerebral) vascular clips
    • Metallic cochlear implants
    • Metallic splinters in eye(s) or other magnetic metallic foreign bodies elsewhere
    • Claustrophobia

  • Relative contra-indications for MRI-contrast agents (50):

    • GFR <30ml/min/1,73m2
    • Previous allergic reaction to MRI contrast agent

  • Contra-indication 18F-Flutemetamol:

    • Known allergic reaction to flutemetamol or polysorbate 80 or any of the excipients.
    • Severe liver dysfunction.

• Patients undergoing CEA:

  • Comorbidity associated with high operative risk
  • Occlusion of the internal carotid artery on the symptomatic side
  • Near occlusion on the symptomatic side
  • Complete infarction of the symptomatic anterior circulation/severe neurological deficit

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
18F-Flutemetamol PET/MRI dynamic	18F-Flutemetamol PET/MRI	All included patients will be patients with a recent stroke and a significant carotid plaque. The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging.
18F-Flutemetamol PET/MRI CEA	18F-Flutemetamol PET/MRI	10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
18F-Flutemetamol PET/MRI	18F-Flutemetamol PET/MRI	The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.

Primary Outcome Measures

Name	Time	Method
18F-Flutemetamol uptake carotids	0-120min	measured as SUV and TBR

Secondary Outcome Measures

Name	Time	Method
18F-Flutemetamol uptake coronaries	0-150min	measured as SUV and TBR
18F-Flutemetamol uptake in the brain	0-150min	measured as SUVR
MRI plaque characteristics carotid	0-150min	semi quantitive analysis
CEA - plaque inflammation	1-14 dys	macrophage content
CEA - plaque amyloid burden	1-14 dys	Immunohistochemistry

Trial Locations

Locations (1)

Maastricht University Medical Centre (MUMC+); 🇳🇱 Maastricht, Limburg, Netherlands